Testing Data
(Peptide Competition: Fibroblasts transfected with oncogenic DSH3-Abl were incubated with 0.50 ug/mL MBS616260, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphotyrosine containing peptide (3), or, the phosphopeptide immunogen (4). The data show that only the peptide corresponding to c-Abl [pY245] blocks the antibody signal, thereby demonstrating the specificity of the antibody.)
Rabbit anti-Human c-Abl Polyclonal Antibody | anti-ABL1 antibody
c-Abl, phosphorylated (Tyr245) (ABL1, v-abl, Abelson Murine Leukemia Viral Oncogene Homolog 1, ABL, c-ABL, JTK7, p150, Proto-Oncogene Tyrosine-Protein Kanase ABL1, v-abl)
Gene Names
ABL1; ABL; JTK7; p150; c-ABL; v-abl; bcr/abl; ABL1
Reactivity
Human
Applications
ELISA, Western Blot
Purity
Affinity PurifiedPurified by immunoaffinity chromatography.
Synonyms
c-Abl; Polyclonal Antibody; phosphorylated (Tyr245) (ABL1; v-abl; Abelson Murine Leukemia Viral Oncogene Homolog 1; ABL; c-ABL; JTK7; p150; Proto-Oncogene Tyrosine-Protein Kanase ABL1; v-abl); Anti -c-Abl; anti-ABL1 antibody
Host
Rabbit
Reactivity
Human
Clonality
Polyclonal
Specificity
Recognizes human c-Abl when phosphorylated at Tyr245. c-Abl Species sequence homology: mouse (92%).
Purity/Purification
Affinity Purified
Purified by immunoaffinity chromatography.
Purified by immunoaffinity chromatography.
Form/Format
Supplied as a liquid in PBS (without Mg2+ and Ca2+), 1mg/ml BSA (IgG, protease free), pH 7.2, 0.05% sodium azide.
Applicable Applications for anti-ABL1 antibody
ELISA (EL/EIA), Western Blot (WB)
Application Notes
Suitable for use in ELISA and Western Blot.
Dilution: Western Blot: 0.1-1ug/ml
Dilution: Western Blot: 0.1-1ug/ml
Immunogen
Synthetic phosphopeptide derived from a region of human c-Abl that contains tyrosine 245. The corresponding phosphorylation site from 1a is tyrosine 226.
Preparation and Storage
May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Testing Data
(Peptide Competition: Fibroblasts transfected with oncogenic DSH3-Abl were incubated with 0.50 ug/mL MBS616260, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphotyrosine containing peptide (3), or, the phosphopeptide immunogen (4). The data show that only the peptide corresponding to c-Abl [pY245] blocks the antibody signal, thereby demonstrating the specificity of the antibody.)
Testing Data
(Peptide Competition: Fibroblasts transfected with oncogenic DSH3-Abl were incubated with 0.50 ug/mL MBS616260, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphotyrosine containing peptide (3), or, the phosphopeptide immunogen (4). The data show that only the peptide corresponding to c-Abl [pY245] blocks the antibody signal, thereby demonstrating the specificity of the antibody.)
Related Product Information for anti-ABL1 antibody
c-Abl is a 140-150kD non-receptor protein tyrosine kinase whose precise functions are not known, but roles for Abl in growth factor and integrin signaling, cell cycle regulation, cytoskeletal reorganization, neurogenesis and responses to DNA damage and oxidative stress have been suggested. c-Abl kinase activity is increased in vivo by diverse physiological stimuli including ionizing radiation, entry into S phase, integrin activation and platelet-derived growth factor (PDGF) stimulation. c-Abl contains various protein binding domains that appear to enable it to regulate the functions of many proteins by forming complexes, most notably three isoforms of the oncogenic protein BCR/ABL. Tyrosine 245 is involved in the activation of c-Abl kinase activity and phosphorylated by Src after PDGF stimulation.
Product Categories/Family for anti-ABL1 antibody
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
Molecular Weight
13,150 Da
NCBI Official Full Name
c-abl
NCBI Official Synonym Full Names
c-abl oncogene 1, non-receptor tyrosine kinase
NCBI Official Symbol
ABL1
NCBI Official Synonym Symbols
ABL; JTK7; p150; c-ABL; v-abl; bcr/abl; ABL1
NCBI Protein Information
tyrosine-protein kinase ABL1; proto-oncogene c-Abl; bcr/c-abl oncogene protein; c-abl oncogene 1, receptor tyrosine kinase; proto-oncogene tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1
UniProt Protein Name
C-abl
Protein Family
UniProt Gene Name
ABL1
UniProt Entry Name
Q13915_HUMAN
NCBI Description
The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11. [provided by RefSeq]
Uniprot Description
Sequence similarities: Contains 1 SH3 domain. RuleBase RU003338
Research Articles on ABL1
1. Among 55 imatinib-resistant CML patients treated with dastinib or nilotinib, baseline mutations in the kinase domain disappeared in 8 patients & new mutations appeared in 9. T315I was the most frequently detected mutation.
2. Observational study of genetic testing. (HuGE Navigator)
3. Overexpression of c-ABL proto-oncogene is associated with enhanced resistance to tamoxifen in breast cancer.
4. Mounting evidence summarized in this review suggests that tyrosine kinase c-Abl and Fyn are critical in the neurodegenerative process which occurs in tauopathies.
5. Review of ABL1 fusion genes identified in T-cell acute lymphoblastic leukemia that provide proliferation and survival advantage to lymphoblasts.
6. Study suggests important roles of BCR-ABL gene expression and its native chromosomal locus for acquisition of BCR-ABL mutations and provides a new tool for further studying resistance mechanisms.
7. Endogenous c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3/alphavbeta5 or by LatB-induced disruption of F-actin.
8. The results show that Bcr-Abl regulates the actin cytoskeleton and non-apoptotic membrane blebbing via a GADS/Slp-76/Nck1 adaptor protein pathway.
9. the additive effects of imatinib and Everolimus on BCR-ABL-expressing cells are at least partly conditional upon the enhanced nuclear accumulation of p145 c-ABL
10. Studiies indicate that KD mutations conferring high-level imatinib resistance are present in patients with de novo CML and in some of them lead to disease progression.
2. Observational study of genetic testing. (HuGE Navigator)
3. Overexpression of c-ABL proto-oncogene is associated with enhanced resistance to tamoxifen in breast cancer.
4. Mounting evidence summarized in this review suggests that tyrosine kinase c-Abl and Fyn are critical in the neurodegenerative process which occurs in tauopathies.
5. Review of ABL1 fusion genes identified in T-cell acute lymphoblastic leukemia that provide proliferation and survival advantage to lymphoblasts.
6. Study suggests important roles of BCR-ABL gene expression and its native chromosomal locus for acquisition of BCR-ABL mutations and provides a new tool for further studying resistance mechanisms.
7. Endogenous c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3/alphavbeta5 or by LatB-induced disruption of F-actin.
8. The results show that Bcr-Abl regulates the actin cytoskeleton and non-apoptotic membrane blebbing via a GADS/Slp-76/Nck1 adaptor protein pathway.
9. the additive effects of imatinib and Everolimus on BCR-ABL-expressing cells are at least partly conditional upon the enhanced nuclear accumulation of p145 c-ABL
10. Studiies indicate that KD mutations conferring high-level imatinib resistance are present in patients with de novo CML and in some of them lead to disease progression.
Similar Products
Product Notes
The ABL1 abl1 (Catalog #AAA616260) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The c-Abl, phosphorylated (Tyr245) (ABL1, v-abl, Abelson Murine Leukemia Viral Oncogene Homolog 1, ABL, c-ABL, JTK7, p150, Proto-Oncogene Tyrosine-Protein Kanase ABL1, v-abl) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's c-Abl can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB). Suitable for use in ELISA and Western Blot. Dilution: Western Blot: 0.1-1ug/ml. Researchers should empirically determine the suitability of the ABL1 abl1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "c-Abl, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
